D. Bell

Cell · 2001–2008

A researcher in the Science corpus: 8 papers; trusts 0 researchers and is trusted by 4 researchers here, as inferred from the citation graph.

Whom D. Bell trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. I. Weinstein

Who trusts D. Bell overall

1. C. Sawyers
2. William Pao
3. Ji Luo
4. Duojia Pan

Papers from D. Bell's perspective

Ordered by how strongly the researchers D. Bell trusts endorse each paper. Same corpus, a different order for every researcher.

1. A small molecule–kinase interaction map for clinical kinase inhibitors (Nature Biotechnology)
2. ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors (Nature Reviews. Cancer)
3. Ras, PI(3)K and mTOR signalling controls tumour cell growth (Nature)
4. Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants (PLoS Medicine)
5. Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase (Cancer Research)
6. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. (Cancer Research)
7. Tumor metastasis: mechanistic insights and clinical challenges (Nature Medicine)
8. Tyrosine kinases as targets for cancer therapy. (New England Journal of Medicine)
9. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. (New England Journal of Medicine)
10. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. (Genes & Development)

Their papers

• salvador Promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. (2002) — 884 citations
• Epidermal growth factor receptor mutations in lung cancer (2007) — 3,159 citations
• Isolation of rare circulating tumour cells in cancer patients by microchip technology (2007) — 3,550 citations
• BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. (2001) — 710 citations
• Detection of mutations in EGFR in circulating lung-cancer cells. (2008) — 1,564 citations
• Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. (2005) — 972 citations
• Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. (2005) — 623 citations
• Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways (2004) — 1,654 citations